Study Suggests Timing of Immunotherapy Could Impact Clinical Outcomes
A systematic review in JAMA Network Open suggests earlier administration of immune checkpoint inhibitor therapies may improve survival outcomes in patients being treated for late-stage solid tumors. The analysis pooled data from 29 studies encompassing more than 6,000 patients. Earlier timing was linked to gains in both survival endpoints, though prospective validation is required before scheduling adjustments can be broadly adopted. The studies covered tumor types like melanoma, gastric, renal cell, esophageal, small cell lung, urothelial, biliary tract, and hepatocellular carcinoma. Twenty-seven of the 29 were retrospective cohorts. The other two comprised a randomized trial in non-small cell lung cancer and a prospective cohort study in head and neck squamous cell carcinoma. The breadth of coverage reflects growing interest in whether treatment timing, not…
